SCHEMBL2260588

SCHEMBL2260588

c1ccc(C2Nc3ccncc3NC2c2ccccc2)cc1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.38
MAPK1 P28482 4/20 0.38
KDM4E B2RXH2 3/20 0.38
L3MBTL1 Q9Y468 2/20 0.38
MEN1 O00255 2/20 0.38
KMT2A Q03164 2/20 0.38
MCL1 Q07820 2/20 0.38
ALDH1A1 P00352 2/20 0.38
HSD17B10 Q99714 2/20 0.38
SMN1; SMN2 Q16637 2/20 0.38
HPGD P15428 1/20 0.38
ALOX15 P16050 1/20 0.38
P2RX7 Q99572 4/20 0.37
GAA P10253 2/20 0.37
IDO1 P14902 1/20 0.37
RECQL P46063 1/20 0.37
RAB9A P51151 1/20 0.37
NOS1 P29475 1/20 0.36
CHRNB2 P17787 1/20 0.35
CHRNA4 P43681 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL12361559 1.00 MAPT (0.38) MAPTMAPK1KDM4EL3MBTL1MEN1
SCHEMBL29264501 0.79 MEN1 (0.45) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL12361556 0.73 ADORA3 (0.39) MAPTMAPK1KDM4EL3MBTL1MEN1
SCHEMBL2258432 0.73 ADORA3 (0.39) MAPTMAPK1KDM4EL3MBTL1MEN1
SCHEMBL25059407 0.71 ADORA3 (0.35) MAPTMAPK1KDM4EL3MBTL1MEN1
SCHEMBL18977996 0.69 NOS2 (0.43) MEN1KMT2AHSD17B10SMN1; SMN2P2RX7
SCHEMBL26703813 0.68 MEN1 (0.44) MAPTKDM4EMEN1KMT2AALDH1A1
SCHEMBL28512297 0.67 MEN1 (0.44) MAPTMAPK1KDM4EMEN1KMT2A
SCHEMBL12361561 0.67 ALDH1A1 (0.37) KDM4EMEN1KMT2AALDH1A1SMN1; SMN2
SCHEMBL25935172 0.67 ADORA3 (0.33) MAPTL3MBTL1GAAIDO1ADORA3

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-7994169-B2 By condensation with a 1,2 carbonyl compound such as glyxoal to form ring and then reduction to form the tetrahydropyrido[3,4-b]pyrazine; acylation catalyst for esterification of ethynylcyclohexanol with acetic anhydride BAYER MATERIALSCIENCE AG (DE) 2011-08-09 US disclosed
EP-2094710-B1 3,4 DIAMINOPYRIDINE DERIVATIVES BAYER MATERIALSCIENCE AG (DE) 2010-05-26 EP disclosed
EP-2094710-A1 3,4 DIAMINOPYRIDINE DERIVATIVES Bayer MaterialScience AG (DE) 2009-09-02 EP disclosed
US-20080176747-A1 3,4-diaminopyridine derivatives BAYER MATERIALSCIENCE AG (DE) 2008-07-24 US disclosed
WO-2008067965-A1 3,4 DIAMINOPYRIDINE DERIVATIVES BAYER MATERIALSCIENCE AG (DE) 2008-06-12 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20080176747-A1 3,4-diaminopyridine derivatives DPYD, QDPR, DDC MAPT 3025/4885MAPK1 1443/4885KDM4E 1152/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.